EDITORIAL SECTIONS

Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.

Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.

Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.

Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”

Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.

Saurabh Shivalkar is a research fellow at Department of Applied Sciences, IIIT Allahabad, India. He did his M. Tech (Biomedical Engineering) from IIIT Allahabad. He has recently filed patent and published multiple papers in the allied areas of biomedical engineering and nanobiotechnology.

Sneha Ranjan is currently pursuing M.Sc. (Biotechnology) at Department of Biotechnology of Babasaheb Bhimrao Ambedkar University, Lucknow. She has worked on projects such as purification and characterisation of enzyme, production of recombinant proteins for diagnostics and therapeutics. She is currently working on polymeric nanocomposites for cancer therapeutics.

With over 15 years of experience, Aarti brings deep expertise across pharmaceutical contract research services and technology‑enabled drug discovery and development. She leads the Contract Research Services program, covering peripheral and ancillary service segments such as tech vendors, eClinical solution providers, central labs, and related ecosystems. Her strengths span market intelligence, forecasting, competitive benchmarking, and strategic opportunity assessment as well as growth advisory services, that consistently support executive decision‑making for global clients. She is  regarded as a trusted growth expert, and is adept in supporting stakeholders navigate industry disruption, accelerate innovation, and seize transformative opportunities across the rapidly evolving Contract Services Landscape.

Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.

Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.

Abhishek Rungta is the Founder and CEO of INT. (Indus Net Technologies), a full-stack digital transformation company serving 500+ enterprise clients across 45 countries. He writes on enterprise AI adoption, digital transformation, and long-term business building.